Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHXNASDAQ:ENVBNASDAQ:PPBTNASDAQ:SXTP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHXAthersys$0.00$0.01▼$1.99$833K-0.91.77 million shsN/AENVBEnveric Biosciences$1.26+0.8%$1.27$1.01▼$11.55$3.09M0.53771,139 shs125,017 shsPPBTPurple Biotech$2.42-1.6%$2.49$2.00▼$13.95$3.27M0.5271,855 shs23,161 shsSXTP60 Degrees Pharmaceuticals$2.16+4.3%$2.60$1.41▼$35.99$3.05M2.88573,456 shs57,505 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHXAthersys0.00%0.00%0.00%0.00%-75.61%ENVBEnveric Biosciences+0.80%+2.44%-7.35%-27.17%-87.48%PPBTPurple Biotech-1.63%-5.47%+5.22%-14.34%+241,999,900.00%SXTP60 Degrees Pharmaceuticals+4.35%-9.62%-6.90%+9.09%+61.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATHXAthersysN/AN/AN/AN/AN/AN/AN/AN/AENVBEnveric Biosciences1.7678 of 5 stars3.52.00.00.00.60.01.3PPBTPurple Biotech1.981 of 5 stars3.54.00.00.00.60.00.6SXTP60 Degrees Pharmaceuticals3.2305 of 5 stars3.35.00.00.02.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHXAthersys 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00693.65% UpsidePPBTPurple Biotech 3.00Buy$33.001,263.64% UpsideSXTP60 Degrees Pharmaceuticals 2.50Moderate Buy$7.00224.07% UpsideCurrent Analyst Ratings BreakdownLatest ATHX, PPBT, SXTP, and ENVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)6/2/2025SXTP60 Degrees PharmaceuticalsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.80 ➝ $7.005/24/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/10/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/24/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/8/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/28/2025SXTP60 Degrees PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/22/2025SXTP60 Degrees PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHXAthersys$146K0.00N/AN/A($1.33) per share0.00ENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/APPBTPurple BiotechN/AN/AN/AN/A$24.74 per shareN/ASXTP60 Degrees Pharmaceuticals$300K10.58N/AN/A($6.38) per share-0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHXAthersys-$72.53M-$2.03N/AN/AN/AN/AN/A-223.03%N/AENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-250.28%-195.57%8/11/2025 (Estimated)PPBTPurple Biotech-$7.24M-$2.62N/AN/AN/AN/A-17.84%-15.44%8/15/2025 (Estimated)SXTP60 Degrees Pharmaceuticals-$7.95M-$50.41N/AN/AN/A-1,947.30%N/A-174.90%8/13/2025 (Estimated)Latest ATHX, PPBT, SXTP, and ENVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025PPBTPurple BiotechN/A-$0.17N/A-$0.17N/AN/A5/15/2025Q1 2025SXTP60 Degrees Pharmaceuticals-$1.31-$1.56-$0.25-$1.56$0.15 million$0.18 million5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHXAthersysN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHXAthersysN/A0.060.06ENVBEnveric BiosciencesN/A4.084.08PPBTPurple BiotechN/A2.722.72SXTP60 Degrees PharmaceuticalsN/A3.142.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHXAthersys19.35%ENVBEnveric Biosciences13.82%PPBTPurple Biotech9.64%SXTP60 Degrees Pharmaceuticals7.96%Insider OwnershipCompanyInsider OwnershipATHXAthersys0.03%ENVBEnveric Biosciences1.10%PPBTPurple Biotech2.98%SXTP60 Degrees Pharmaceuticals10.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHXAthersys2461.72 million61.70 millionNo DataENVBEnveric Biosciences202.47 million2.45 millionNot OptionablePPBTPurple Biotech201.33 million1.29 millionOptionableSXTP60 Degrees Pharmaceuticals31.47 million1.32 millionNot OptionableATHX, PPBT, SXTP, and ENVB HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals (NASDAQ:SXTP) Cut to Sell at Wall Street ZenJune 14, 2025 | americanbankingnews.com60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives "Sell (E+)" Rating from Weiss RatingsJune 12, 2025 | americanbankingnews.com60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Director Cheryl Xu Acquires 5,000 SharesJune 6, 2025 | insidertrades.com60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026June 5, 2025 | nasdaq.com60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle FormatJune 4, 2025 | globenewswire.comBabesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees PharmaceuticalsJune 3, 2025 | globenewswire.com60 Degrees Pharmaceuticals Announces First Quarter 2025 ResultsMay 15, 2025 | globenewswire.comBabesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma SurveyApril 22, 2025 | globenewswire.comWhy 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday?April 10, 2025 | insidermonkey.comGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21April 10, 2025 | globenewswire.comGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21April 10, 2025 | globenewswire.comSixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public HealthApril 8, 2025 | globenewswire.com60 Degrees Pharmaceuticals, Inc.April 4, 2025 | uk.investing.com60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVFebruary 21, 2025 | accessnewswire.com60 Degrees Pharmaceuticals announces 1-for-5 reverse stock splitFebruary 20, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals, Inc. Announces 1-for-5 Reverse Stock Split to Comply with Nasdaq Listing RequirementsFebruary 20, 2025 | quiverquant.com60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock SplitFebruary 20, 2025 | globenewswire.com60 Degrees says FDA does not object to tafenoquine import planFebruary 11, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals, Inc. Receives FDA Approval for Importing KODATEF® as Preemptive Measure for ARAKODA® Supply StabilityFebruary 11, 2025 | quiverquant.comSixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®February 11, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATHX, PPBT, SXTP, and ENVB Company DescriptionsAthersys NASDAQ:ATHXAthersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.Enveric Biosciences NASDAQ:ENVB$1.26 +0.01 (+0.80%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.25 -0.01 (-1.19%) As of 06/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Purple Biotech NASDAQ:PPBT$2.42 -0.04 (-1.63%) Closing price 06/18/2025 03:47 PM EasternExtended Trading$2.42 +0.00 (+0.21%) As of 06/18/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.60 Degrees Pharmaceuticals NASDAQ:SXTP$2.16 +0.09 (+4.35%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.12 -0.04 (-1.62%) As of 06/18/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
